Topics

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

09:47 EDT 1 Aug 2019 | Labiotech.eu

Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […]

The post Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III appeared first on Labiotech.eu.

Original Article: Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

NEXT ARTICLE

More From BioPortfolio on "Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...